Sub-Navigation

• Investor News
• Ad-hoc Publications
• Press
• Archive
  • Overview
  • Investor News 2009
  • Investor News 2008
  • Investor News 2007
  • Investor News 2006
  • Investor News 2005
  • Investor News 2004
  • Investor News 2003
  • Investor News 2002
  • Investor News 2001
  • Investor News 2000
  • Ad-hoc 2009
  • Ad-hoc 2008
  • Ad-hoc 2007
  • Ad-hoc 2006
  • Ad-hoc 2005
  • Ad-hoc 2004
  • Ad-hoc 2003
  • Ad-hoc 2002
  • Ad-hoc 2001
  • Ad-hoc 2000
  • Ad-hoc 1999
  • Ad-hoc 1998

Bayer Links

• Bayer Global
• Sustainability
• Press

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• News
• Archive
• Investor News 2007

Search

Here you find Investor News of year 2007. Ad-hoc messages issued in year 2007 can be found here.

Publications of the previous years are offered in the Archive Overview.

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR News via E-Mail, RSS Feed or SMS.

Monday December 10, 2007

VTE Prevention After Major Orthopaedic Surgery:

Three Pivotal Phase III Trials Show Superior Efficacy of Rivaroxaban over Standard of Care with Enoxaparin

Consistent results across three RECORD trials involving nearly 10,000 patients / Venous thromboembolism considered the most frequent and potentially fatal complication following major orthopaedic surgery / No evidence of liver signal attributable to rivaroxaban has been seen

Saturday December 08, 2007

VTE Prevention After Hip Replacement Surgery:

Pivotal Phase III Data Show Superior Efficacy of Rivaroxaban over Enoxaparin

Head-to-Head Study Demonstrates Similar and Low Rate of Bleeding for Both Drugs

Monday December 03, 2007

Bayer Schering Pharma paves the way to the next important oral contraceptive milestone

Monday November 26, 2007

Bayer CropScience, Mertec and M.S. Technologies to co-develop new soybean trait products

Joint collaboration will bring alternative herbicide tolerant systems and more choice for farmers in weed management

Monday November 19, 2007

Nexavar® First FDA-Approved Drug Therapy for Liver Cancer

Only Systemic Therapy Proven to Significantly Improve Overall Survival in Patients with Liver Cancer

Friday November 09, 2007

New Phase III Trial Results for Rivaroxaban to be Presented at the 49th Annual Meeting of the American Society of Hematology

Endpoints Met for RECORD1 and RECORD2 Trials in Total Hip Replacement Surgery

Tuesday November 06, 2007

Fall Financial News Conference in Leverkusen

Bayer expects a record year in 2007

Third-quarter sales grow 4.5 percent to EUR 7,793 million / EBITDA before special items advances 6.9 percent to EUR 1,559 million / EBIT before special items climbs 23.9 percent to EUR 953 million / Group net income of EUR 1,175 million after one-time positive tax effect

Monday November 05, 2007

Bayer Temporarily Suspends Global Trasylol® Marketing

Wednesday October 31, 2007

Prevention of Venous Thromboembolism after Major Orthopedic Surgery:

Bayer HealthCare Submits Rivaroxaban for European Approval

Data Package for Rivaroxaban Involves Nearly 10,000 Patients in Three Phase III Trials

Tuesday October 30, 2007

Bayer sells Hennecke to Adcuram

Tuesday October 30, 2007

Nexavar® Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe

Only Systemic Therapy Shown to Significantly Extend Survival in Patients with Most Common Form of Liver Cancer

Monday October 29, 2007

Therapy of multiple sclerosis

BEYOND study: Results do not support regulatory filing for Betaferon® 500 mcg

Betaferon® 250 mcg is optimal Betaferon® dose based on high efficacy and excellent tolerability / Study unable to show superiority of Betaferon® 500 mcg compared to Betaferon 250® mcg and Copaxone®

Friday October 26, 2007

Court rules in favor of Bayer over Avelox® patents

Friday October 26, 2007

Bayer MaterialScience raises prices for polycarbonates

Thursday October 25, 2007

Bayer Issues Additional Guidance to Physicians on Trasylol®

Tuesday October 23, 2007

B-cell Chronic Lymphocytic Leukemia (B-CLL):

MabCampath® Receives Positive Opinion from European Committee for Medicinal Products for Human Use

Monday October 15, 2007

New top-line efficacy data presented from phase II trial of Alemtuzumab in multiple sclerosis:

Three-year analysis demonstrates continued robust treatment effect of Alemtuzumab compared to Rebif®

Monday October 01, 2007

Age-related Macular Degeneration (AMD):

Bayer HealthCare Announces Positive Phase 2 Results for the VEGF Trap-Eye

Data presented at the Retina Society Conference in Boston

Wednesday September 26, 2007

Bayer Schering Pharma AG, Germany, and Genzyme Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis

Wednesday September 26, 2007

Bayer MaterialScience to build a world-scale plant for polymer polyols in Antwerp

Total investment of around EUR 40 million / Commissioning scheduled for late 2008 / Efficient production process delivers optimized products

Tuesday September 25, 2007

September 26, 2007:

Last trading day for Bayer ADSs on Wall Street

Friday September 21, 2007

Hepatocellular carcinoma:

Nexavar® Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Treatment of Liver Cancer

Thursday September 20, 2007

B-cell chronic lymphocytic leukemia:

FDA Approves Expanded Labeling for Campath® to Include First-line Treatment for Leading Form of Adult Leukemia

Study data demonstrated improved progression-free survival with Campath

Friday September 14, 2007

Bayer completes acquisition of U.S. biologics manufacturing facility from Novartis

Thursday September 13, 2007

FDA Advisory Committees Recommend Continued US Marketing Authorization for Trasylol

Committees also recommend further changes to US Label for Trasylol and additional safety studies

Wednesday September 12, 2007

Bayer MaterialScience examines feasibility of 400,000-ton MDI plant in Europe

Total worldwide capacity would increase to 1,850,000 tons a year / Commissioning could take place in 2012

Thursday September 06, 2007

Bayer CropScience CEO Professor Friedrich Berschauer:

"Innovation and new technologies will help us to meet the growing demand for food and energy-producing plants"

Stronger research focus on the needs of the "new ag economy" / Promising active ingredient and plant biotechnology pipeline / Seed and biotech sales to reach EUR 1 billion in the longer term / Successful first half of 2007 indicates optimistic outlook for the full year

Wednesday September 05, 2007

Bayer intends to delist from the New York Stock Exchange

Purpose is to reduce complexity and costs / Transparent financial reporting will continue

Tuesday September 04, 2007

New insecticidal active ingredient flubendiamide granted regulatory approval in major Asian markets

Product launch strengthens Bayer CropScience's portfolio in the region

Thursday August 30, 2007

Bayer HealthCare Strengthens US Consumer Health Business with Acquisition of Citracal®

Addition of Leading Calcium Brand Enriches Consumer Care Division's Key Nutritionals Product Portfolio

Monday August 27, 2007

Bayer MaterialScience is to transfer EXATEC shares to GE Plastics

Monday August 27, 2007

Nexavar Significantly Improved Overall Survival in Phase III Asia-Pacific Liver Cancer Trial

Trial to be Stopped Early to Allow All Patients Access to Nexavar

Tuesday August 21, 2007

Medtronic and Bayer HealthCare announce alliance to provide blood glucose meter to Medtronic patients outside the Unites States

New blood glucose meter to provide advanced therapy options for people with diabetes beginning in Canada and Europe

Wednesday August 15, 2007

Novel herbicidal active ingredient pyrasulfotole granted first regulatory approval

Bayer CropScience to launch new cereal herbicide Huskie® in the United States in 2008

Tuesday August 07, 2007

Gratifying trend in the second quarter of 2007

Bayer continues on a path of growth

Sales up 22 percent to EUR 8,217 (6,736) million / Underlying EBITDA climbs 39 percent to EUR 1,806 (1,303) million / Underlying EBIT rises 30 percent to EUR 1,185 (911) million / Net income advances by 46 percent to EUR 660 (452) million / Underlying EBITDA margin above 20 percent expected for the full year

Monday August 06, 2007

Bayer HealthCare and Nektar Therapeutics To Develop Innovative Therapy For Pneumonia

Friday August 03, 2007

Bayer HealthCare and Regeneron initiate Phase 3 global development program for VEGF Trap-Eye in wet age-related macular degeneration (AMD)

Study will compare the VEGF Trap-Eye to ranibizumab (Lucentis®)

Thursday July 12, 2007

YAZ® approved in the Netherlands as European Reference Member State

Sunday July 08, 2007

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor, Shows a Significant Reduction in Deep Vein Thrombosis and Pulmonary Embolism Compared with Enoxaparin with Similarly Low Bleeding Rates

Monday July 02, 2007

Bayer MaterialScience completes Taiwan Ure-Tech acquisition

Aiming to be the global number one in thermoplastic polyurethanes (TPU)

Monday July 02, 2007

Dow Acquires Wolff Walsrode from Bayer

Dow Secures Application Expertise and Broader Cellulosics Offering for End-use Segments

Wednesday June 27, 2007

Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer

Nexavar is First Drug Therapy to Demonstrate Significant Survival Benefit in Liver Cancer

Wednesday June 20, 2007

Bayer CropScience and Monsanto enter long-term business and license agreements for key enabling technologies

Agreements aim at creating new choices and more options for farmers

Tuesday June 19, 2007

Bayer CropScience completes acquisition of US cotton seed company Stoneville

Tuesday June 19, 2007

Bayer HealthCare Investor Day 2007:

Bayer raises guidance for 2007 and 2009

Underlying EBITDA margin of the Bayer Group to exceed 22 percent by 2009 / Improved earnings forecast for Bayer HealthCare / Integration of Bayer Schering Pharma proceeding more quickly than planned / New research strategy adopted and pharmaceutical pipeline optimized / Current clinical studies confirm the potential of rivaroxaban / Nexavar® submitted in HCC / New drug to control bleeding during surgery inlicensed

Monday June 04, 2007

Bayer Schering Pharma AG will terminate registration with the U.S. SEC

Monday June 04, 2007

Phase 3 Study: Nexavar® Significantly Extends Overall Survival by 44% in Liver Cancer Patients

First Agent Ever to Demonstrate Significant Survival Benefit in Liver Cancer

Thursday May 31, 2007

Bayer CropScience agrees to acquire US cotton seed company Stoneville for US-$ 310 million

Acquisition of leading US cotton business expected to bolster growth strategy

Thursday May 24, 2007

Annual Stockholders' Meeting of Bayer Schering Pharma AG, Berlin, Germany:

Integration of Bayer Schering Pharma progressing rapidly

Positive business performance in the first quarter of 2007 / Domination and profit-and-loss transfer agreement confirmed

Wednesday May 09, 2007

Bayer MaterialScience expands production capacities in Shanghai for coating and adhesive raw materials

New plant for polyurethane dispersions / Polyisocyanate production to be expanded

Tuesday May 08, 2007

Bayer publishes interim report for the first quarter of 2007

Thursday May 03, 2007

Bayer Schering Pharma, Berlin, Germany, prevails in litigation over domination agreement

Tuesday May 01, 2007

First-of-its-Kind Data Show:

Immediate Treatment of Early MS Patients with Betaferon® Significantly Delayed Permanent Disability

Risk to confirmed EDSS progression reduced by 40 percent compared to delayed treatment

Friday April 27, 2007

Werner Wenning at the Annual Stockholders' Meeting in Cologne:

Bayer off to an excellent start in 2007

Preliminary figures show substantial growth in first-quarter sales and earnings / Positive outlook for full year confirmed / Elections to the Supervisory Board

Thursday April 26, 2007

Bayer exceeds consensus estimates for the first quarter of 2007

Preliminary figures show sales up 23 percent to EUR 8.3 billion / Underlying EBITDA climbs 27 percent to EUR 2.0 billion / Net income of EUR 2.8 billion including divestment proceeds / Positive outlook for full year 2007 confirmed

Wednesday April 18, 2007

Novel cholesterol uptake inhibitor ZETIA® approved in Japan

Product will be co-marketed by Bayer Yakuhin Ltd. and Schering-Plough K.K.

Wednesday April 04, 2007

Genzyme Files for Expanded Label for Campath® as First-Line Treatment for B-CLL Patients

Wednesday March 28, 2007

Bayer CropScience aims to grow in China:

Sales in the People's Republic forecast to top EUR 100 million in the medium term

Plans for two joint ventures for hybrid rice business and expansion of crop protection production

Tuesday March 27, 2007

Positive interim Phase 2 Data reported for VEGF Trap-Eye in age-related macular degeneration

Bayer HealthCare and Regeneron plan to begin Phase 3 program in 2nd half of 2007

Monday March 26, 2007

Bayer deal with Novartis improves profit outlook for Betaseron® franchise

- Bayer Schering Pharma AG, Germany, acquires U.S. Biologics manufacturing facility from Novartis/ - Bayer will stop paying Novartis current royalty on Betaseron® from October 2008/ - Bayer will provide licensing rights to Novartis to establish its own brand of interferon beta-1b from 2009 forward

Thursday March 15, 2007

Werner Wenning at the Spring Financial News Conference on March 15

2006 a record year for Bayer

Sales up 17.2% to EUR 28,956 million / EBITDA before special items climbs 21.3% to EUR 5,584 million / EBIT before special items advances 14.2% to EUR 3,479 million / Sales and underlying EBITDA expected to grow more than 10% in 2007 / Bayer Group targets underlying EBITDA margin of about 22% for 2009 / Bayer HealthCare aims for an underlying EBITDA margin of some 27% in 2009

Thursday March 15, 2007

Supervisory Board of Bayer AG proposes stockholders' representatives for new term of office

Monday March 12, 2007

Bayer increases dividend to EUR 1.00

Total dividend payout rises 10.1 percent to EUR 764 million

Friday March 02, 2007

Bayer HealthCare announces concrete plans for the global synergy goals and job cuts

Savings in the order of EUR 700 million annually from 2009 / 6,100 jobs to be cut globally, 1,500 of these in Germany / Headquarters in Berlin to remain the largest global location of Bayer Schering Pharma AG, Germany

Thursday March 01, 2007

Bayer MaterialScience raises prices for Apec ®, Makrolon®, Bayblend® and Makroblend® polycarbonates

Friday February 23, 2007

Dr. Axel Steiger-Bagel appointed Chief Administration Officer of Bayer MaterialScience AG

Tuesday February 20, 2007

Bayer HealthCare strengthens presence in Eastern Europe

More than 200 staff for Marketing and Sales integrated in Russia, Belarus, the Ukraine and Kazakhstan

Monday February 12, 2007

New organizational structure to strengthen Bayer MaterialScience business

Business Unit Heads to become members of Executive Committee

Monday February 12, 2007

Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer

Trial To Be Stopped Early Based on Positive Outcome

Thursday February 08, 2007

EU-Approval for Continuous Infusion of KOGENATE® Bayer

Excellent Hemostatic Control Achieved

Tuesday February 06, 2007

Bayer Responds to study and commentary published in Journal of American Medical Association (JAMA)

Tuesday February 06, 2007

Bayer MaterialScience intends to expand annual capacity of TDI production facility in Shanghai to 300,000 tons

Innovative production technology means much lower costs

Thursday February 01, 2007

Bayer HealthCare and CSL Behring Extend Agreement for Supply of Recombinant Factor VIII

Global distribution deal extended through 2017

Thursday February 01, 2007

Bayer completes sale of H.C. Starck to Advent International and The Carlyle Group

Tuesday January 30, 2007

Innovative Long-Acting Contraceptive Product Mirena® approved in Japan

Monday January 29, 2007

New indication for YAZ® approved in the U.S.

Friday January 26, 2007

Oral formulation of Fludara® approved in Japan

Thursday January 25, 2007

Bayer discontinues Trasylol® clinical trial program in non-CABG indications

Recent label changes for Trasylol® in CABG indication impact the clinical trial development in other indications

Wednesday January 24, 2007

New active ingredient controls weeds in corn

Tembotrione given first regulatory approval

Bayer CropScience launches herbicide Laudis® in Austria, its first market

Thursday January 18, 2007

Extraordinary Stockholders' Meeting in Berlin

Squeeze-out to be implemented at Bayer Schering Pharma

Wednesday January 17, 2007

Extraordinary Stockholders' Meeting in Berlin

Decision imminent on squeeze-out at Bayer Schering Pharma

Proposed cash compensation of EUR 98.98 per Bayer Schering Pharma share / Integration process making good headway

Wednesday January 17, 2007

Andreas Busch and Kemal Malik appointed to the Board of Management of Bayer Schering Pharma

Marc Rubin, Board member for R&D, resigns his position

Wednesday January 03, 2007

Divestment of Bayer's diagnostics business to Siemens completed

Wednesday January 03, 2007

Bayer MaterialScience lifts TDI Force Majeure